ReviewBlood2019
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.
Review in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04562818 (Results From a Mexican Long-term Multicentric Study on Acute Promyelocytic Leukemia.), which is not on this map. Cited by 355 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Results From a Mexican Long-term Multicentric Study on Acute Promyelocytic Leukemia.
Who cites it
355 citing papers in PubMed, 4 syntheses or guidelines pooled it, 640 citations in OpenAlex.
- Pooled it
- Early mortality in patients with acute promyelocytic leukemia: a systematic review and meta-analysis.Critical care (London, England) · 2025Pooled it
- Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 2: hematologic malignancy.International journal of hematology · 2025Guideline
- A systematic review and meta-analysis of recombinant human soluble thrombomodulin for the treatment of DIC associated with hematological malignancies.International journal of hematology · 2024Pooled it
- Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenic trioxide for unresectable large or huge hepatocellular carcinoma: a prospective study.European radiology · 2024Trial
- Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group.Blood cancer journal · 2023Trial
- Trial
- Targeting histamine signaling: repurposing antihistamines for cancer chemotherapy and immunotherapy.Archives of pharmacal research · 2026Review
- Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies.British journal of cancer · 2026Review
- Retinoic acid in health and disease.Signal transduction and targeted therapy · 2026Review
- Rethinking Drug Resistance in Acute Promyelocytic Leukemia: The Regulated Cell Death Network as an Integrative Framework.Biomolecules · 2026Review
- Marantic endocarditis: a multidisciplinary case in which the etymology helps to determine the aetiology.European heart journal. Case reports · 2026Article
- Article
- Improved real-world outcomes of patients with acute promyelocytic leukaemia treated with first-line arsenic trioxide in specialized centres in Portugal through a 24/7 phone-based referral.British journal of haematology · 2026Article
- Article
- Renaissance of Traditional Mineral Drugs in Cancer: Advanced Delivery Strategies and Bioengineering Approaches.Pharmaceutics · 2026Review
- When effective anticancer therapies are, in fact, destabilizing the tumor's Group Phenotypic Composition.NPJ precision oncology · 2026Review
- Common Hematologic Emergencies-Acute Promyelocytic Leukemia and Microangiopathic Hemolytic Anemias-A Pivotal Role of Clinical Laboratory.International journal of laboratory hematology · 2026Review
- A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA/PALG study.Haematologica · 2026Article
- Perindopril and L‑arginine protect against arsenic trioxide-induced neurotoxicity via Keap1/Nrf2/HO‑1 activation and suppression of neuroinflammation and apoptosis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
295 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 19 institutions in 12 countries.
Funding
Abstract
Since the comprehensive recommendations for the management of acute promyelocytic leukemia (APL) reported in 2009, several studies have provided important insights, particularly regarding the role of arsenic trioxide (ATO) in frontline therapy. Ten years later, a European LeukemiaNet expert panel has reviewed the recent advances in the management of APL in both frontline and relapse settings in order to develop updated evidence- and expert opinion-based recommendations on the management of this disease. Together with providing current indications on genetic diagnosis, modern risk-adapted frontline therapy, and salvage treatment, the review contains specific recommendations for the identification and management of the most important complications such as the bleeding disorder APL differentiation syndrome, QT prolongation, and other all-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.